Regis, honestly.. your enthusiasm hasn’t weakened at all? Share price has disintegrated, Dr KSS doesn’t believe in product or the team anymore, and internal approval seems years away. I’m starting to think the upcoming partner deals might be underwhelming also. I’ve always kept the faith, even adding here and there. Now, kind of just waiting to get out.
One should beware of a scenario in which a company registers the same patent in a large number of countries and declares a large number of patents. Also, the December 2018 510(k) has led to what? 3-D Matrix has launched a hemostat for use in GI endoscopy in Europe. Question is: not about differences in commercial product (ARTH has none at this time), but what are differences in technology? Is there a significant, useful differentiation? If so, what is it?
News 
Market Data 
Discover 
AI
